XT
AARD

XTX Topco’s Aardvark Therapeutics AARD Stock Holding History

XTX Topco’s Portfolio AARD Stock Details AARD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$75.1K Sell
19,915
-5,633
-22% -$58.4K ﹤0.01% 3198
2025
Q4 		$335K Buy
+25,548
New +$319K 0.01% 1969

Other funds holding AARD

DC
Decheng Capital Menlo Park, California $661M AUM 299.97% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TAM
TFG Asset Management Grand Cayman, Cayman Islands $515M AUM 24.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

XTX Topco's AARD Position: Q1 2026 in Review

XTX Topco reduced its Aardvark Therapeutics (AARD) stake by 22% in Q1 2026, selling an estimated $58.4K and leaving 19,915 shares worth $75.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3198.

XTX Topco first reported a position in AARD in Q4 2025 and has held it in 2 quarters since. The position peaked at $335K in Q4 2025. 79 funds tracked by Wall St. Rank hold AARD as of Q1 2026.

  • XTX Topco held 19,915 shares of Aardvark Therapeutics worth $75.1K as of Q1 2026.
  • XTX Topco sold 5,633 Aardvark Therapeutics shares in Q1 2026, an estimated $58.4K.
  • Aardvark Therapeutics made up ﹤0.01% of XTX Topco's portfolio in Q1 2026, its #3198 holding.
  • XTX Topco first reported a position in Aardvark Therapeutics in Q4 2025 and has held it in 2 quarters since.
  • XTX Topco's Aardvark Therapeutics position peaked at $335K in Q4 2025.
  • 79 funds tracked by Wall St. Rank held Aardvark Therapeutics as of Q1 2026.

Based on XTX Topco's 13F filing for Q1 2026, filed 15 May 2026.